Woodcliff Lake, N.J.-based Barr Pharmaceuticals raised its bid for Pliva to $2.5 billion. Barr's chief rival in the Pliva acquisition is Iceland-based Actavis, which offered $1.85 billion for Pliva, based in Croatia. If Pliva accepts Barr's offer, Barr would become the world's third-largest generic drug manufacturer behind second-place Novartis and No. 1 Teva.
Woodcliff Lake, N.J.-based Barr Pharmaceuticals raised its bid for Pliva to $2.5 billion. Barr's chief rival in the Pliva acquisition is Iceland-based Actavis, which offered $1.85 billion for Pliva, based in Croatia. If Pliva accepts Barr's offer, Barr would become the world's third-largest generic drug manufacturer behind second-place Novartis and No. 1 Teva. Meanwhile, the FDA sent a warning letter to Actavis executives after inspectors found deficiencies in the company's New Jersey manufacturing plant. Actavis said that it has taken actions in response to the warning.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Antiseizure Medications Linked to Serious Potential Reaction, FDA Warns
November 30th 2023Levetiracetam and clobazam can cause Drug Reaction with Eosinophilia and Systemic Symptoms, which can start as a rash but progress quickly, potentially resulting in injury to internal organs, hospitalization, and death.
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.